Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

After the presentation, there will be a question and answer session. To raise your hand to ask a question, press star 11. To lower your hand, you may press star 11 again. Please be advised that today's call is being recorded. With that, I would like to turn the call over to Eric Chiarelli, Fathom's Head of Investor Relations. Please go ahead. Thank you, Operator. Hello, everyone, and thank you for joining us this morning to discuss FASM's third quarter 2025 results. This morning's presentation will include remarks from Steve Basta, our president and CEO, and Sanjeev Narula, our chief financial and business officer. Robert Breedlove, our principal accounting officer, will be joining for the Q&A portion of today's call. A couple of notes before we get started. Earlier this morning, we issued a press release detailing the results we will be discussing during the call. A copy of that press release can be found under the news releases section of our corporate website. Further, the recording of today's webcast and the slides we'll be reviewing can be found on our corporate website under the events and presentation section. Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyond FADM's control. Actual results may materially differ from the forward-looking statements, and any such risks may materially adversely affect our business and results of operations and the trading prices for Fathom's common stock. A discussion of these statements and risk factors is available on the current Safe Harbor slide, as well as in the risk factors section of our most recent Form 10-K and subsequent SEC filings. All forward-lookin...